Document Type : Short Communications
Department of Pathology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Department of Hematology and Oncology, School of Medicine, Pontificia Universidad Catolica de Chile, Santiago, Chile.
Background: Lung cancer (LC) is the second leading cause of cancer death in Chile, causing >3,000 deaths every
year. Epidemiological LC data in Chile is scarce and scattered. Here, we aimed to quantify the prevalence of Epidermal
Growth Factor Receptor (EGFR) gene mutations in a Chilean cancer center. These data may identify individuals that
could benefit from targeted therapies such as Tyrosine Kinase Inhibitors (TKIs). Methods: A total of 1,405 Biopsies
from 1,381 LC patients were retrospectively analyzed retrieving clinical data from EGFR mutants including age,
gender, histological type, smoking habits and type of EGFR mutation. We also analyzed overall survival (OS) rates.
Results: From all patients 21.7% had clinically relevant EGFR mutations, and a median age at diagnosis of 65 years.
Most were female (64%), classified as adenocarcinomas (94.5%), and non-smokers/light smokers (93.1%). The most
prevalent mutation was exon-19 deletions (50.6%) followed by Leucine-to Arginine 858; OS was 15 months. Clinical
follow-up information was available for 83 patients. The use of TKIs in these patients significantly improved OS.
Conclusion: The prevalence of EGFR mutations in the studied population was 21.7%, comparable to other countries
in Latin America. The most frequent EGFR mutation was exon-19 deletion, OS in this group was 15 months, and TKIs
significantly improved OS.